The listed biotech sector has had a significant sell-off over the past year but innovations still abound, leading investors to ...
Investors are accused of being ‘theme junkies’ as they chase the latest mega-trend but which theme has seen the strongest ...
The COVID-19 vaccine roll-out may be slow in Australia but exposure to one of its creators has boosted the Platinum ...
Australian investors tend to have a concentrated domestic exposure to biotechnology but may be missing the growth and diversification offered ...
Global healthcare stocks are expected to perform strongly over the long term thanks to a huge boost in healthcare spending ...
As markets react to the news of a successful COVID-19 vaccine trial from US pharma Pfizer and German biotech firm ...
Biotechnology is just as exciting as Amazon or Afterpay but often fails to receive the same attention, according to Platinum.
Pengana has increased its weighting to healthcare in its High Conviction Equities fund as it is confident in the recovery ...
Despite the world rushing to find a vaccine for COVID-19, biotech and healthcare funds have not been able to maintain ...
In financial markets, excitement drives headlines. Equity markets rise, fall, and recover — creating stories that capture attention. Yet sustainable...
Winner of Executive of the Year – Funds Management 2025After years at Goldman Sachs and Credit Suisse, Jonathan Belz founded...
Cryptocurrency liquidity has become a cornerstone of sophisticated wealth management strategies, with real-time settlement capabilities revolutionizing traditional investment approaches. The...
In this episode of Relative Return, host Laura Dew chats with Roy Keenan, co-head of fixed income at Yarra Capital...
